PINK:KHTRF
Knight Therapeutics Inc. Stock News
$4.18
+0 (+0%)
At Close: Jun 17, 2024
Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript
03:53am, Saturday, 11'th May 2024
Knight Therapeutics, Inc. (OTCPK:KHTRF) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind Utchanah - CFO Conference
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusi
Knight Therapeutics Reports First Quarter 2024 Results
07:30am, Thursday, 09'th May 2024
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financia
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
06:32pm, Wednesday, 08'th May 2024
MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
07:30am, Thursday, 02'nd May 2024
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 fin
Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript
12:15pm, Thursday, 21'st Mar 2024
Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
07:30am, Thursday, 21'st Mar 2024
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financ
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
07:30am, Thursday, 14'th Mar 2024
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and y
Knight Therapeutics Inc. Celebrates its First Decade of Success
07:30am, Wednesday, 28'th Feb 2024
MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year ann
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
05:30pm, Wednesday, 21'st Feb 2024
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit
Knight Therapeutics Announces Launch of Bijuva® in Canada
07:30am, Tuesday, 06'th Feb 2024
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
07:30am, Thursday, 04'th Jan 2024
MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada
Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Call Transcript
01:42am, Sunday, 12'th Nov 2023
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Samira Sakhia - President and Chief Executive Officer Arvind Utchanah - Chief F
Knight Therapeutics Reports Third Quarter 2023 Results
07:30am, Thursday, 09'th Nov 2023
MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financi
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
07:30am, Thursday, 02'nd Nov 2023
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 fi
